Subscribe
shutterstock_olivier_le_moal_756213100
Olivier Le Moal / Shutterstock.com
19 March 2020AmericasRory O'Neill

PacBio pledges to fight invalidation of patents after bitter dispute

California-based  Pacific Biosciences (PacBio) has accused a UK rival of exploiting the coronavirus pandemic in a patent infringement trial.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Personal Genomics takes PacBio dispute to Chinese court
22 May 2020   Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More features

Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation: Follow the money (Part I)
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Barnes & Thornburg reveals five new IP leaders
Former PTAB judge joins Sterne Kessler
GSK escalates mRNA COVID-19 vaccine dispute